Decades-Long 'Undruggable' Target Falls: New Drug Nearly Doubles Pancreatic Cancer Survival

A 60% reduction in the risk of death. That is the number coming out of the daraxonrasib clinical trial, and it deserves to be read twice. For patients with advanced pancreatic cancer — a disease with a five-year survival rate that has stubbornly hovered near 12% for decades — this is not incremental progress. It is a structural shift in what medicine can do. The target is KRAS, a mutation present in roughly 90% of pancreatic tumors. Scientists have known about it since the 1980s. For most of that time, the consensus was blunt: KRAS couldn't be drugged. Its surface offered no clean binding site, no obvious molecular handle. That consensus held for forty years. Daraxonrasib broke it. The drug works by locking KRAS in an inactive state, cutting off the molecular signal that tells cancer cells to keep dividing. The clinical trial results, reported via Science Daily, show the treatment nearly doubled median survival for patients with advanced disease compared to existing standard-of-care options. That 'nearly doubled' figure is not a statistical footnote — in late-stage pancreatic cancer, where median survival is often measured in months, doubling that window is the difference between a patient seeing a grandchild's birthday or not. The specificity of the mechanism also matters: because KRAS is present in the vast majority of pancreatic tumors, this isn't a niche solution for a rare subtype. It is broadly applicable. Pancreatic cancer kills roughly 50,000 Americans annually and has long been the cancer researchers feared most — diagnosed late, resistant to most therapies, and historically immune to the targeted drug revolution that transformed treatment for breast, lung, and blood cancers. Daraxonrasib does not close that chapter entirely, but it opens one that many in oncology genuinely believed would stay shut. Science moved. The wall came down.